Thomas P R, Lindblad A S
Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO.
Radiother Oncol. 1988 Dec;13(4):245-52. doi: 10.1016/0167-8140(88)90219-8.
The Gastrointestinal Tumor Study Group (GITSG) protocol GI-7175 randomized 227 patients between 1975 and 1980 following complete surgical resection of stages B2 and C rectal adenocarcinoma to four treatment arms: (1) no adjuvant therapy, (2) chemotherapy only, (3) radiotherapy only, and (4) radiotherapy and chemotherapy (combined modality). The results of the study showed an advantage for combined modality treatment over no adjuvant therapy for time to recurrence (p = 0.005) and for survival (p = 0.01). Severe acute toxicity was frequent in the combined modality arm (61%) but late effects, including radiation enteritis, have been infrequent. We conclude that postoperative adjuvant therapy is indicated in certain stages of rectal carcinoma and that the present state of knowledge suggests combined modality therapy.
胃肠道肿瘤研究组（GITSG）的GI - 7175方案在1975年至1980年间，将227例B2期和C期直肠腺癌患者在接受完整手术切除后随机分为四个治疗组：（1）不进行辅助治疗；（2）仅进行化疗；（3）仅进行放疗；（4）放疗加化疗（综合治疗）。研究结果显示，综合治疗组在复发时间（p = 0.005）和生存率（p = 0.01）方面优于不进行辅助治疗组。综合治疗组严重急性毒性反应频繁（61%），但包括放射性肠炎在内的晚期效应并不常见。我们得出结论，直肠癌某些阶段需要进行术后辅助治疗，且就目前的知识水平而言，综合治疗是合适的。
